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Abstract: 28 Clinical records of dogs with spontaneous degenerative mitral valve disease (DMVD) with 29 clinical signs related to congestive heart failure (CHF) that had been recruited during routine 
Introduction

53
Degenerative mitral valve disease is the most common heart disease in middle-old aged and 54 medium-sized dogs. It is characterized by a slow progression over years, and in many affected 55 dogs, because of the age of onset, does not always progress to clinical signs of congestive 56 heart failure (CHF) [1, 2, 3] . Some authors have reported a survival time of between 5 to 14 57 months after the onset of clinical signs [4, 5] . Although DMVD has been studied for more than 58 40 years, its treatment remains a challenge for the clinician.
59
Many advances have been made regarding diagnosis, imaging, medical and surgical therapy, 60 however few studies have evaluated the natural history and prognostic factors of the disease 61 in dogs [3, 6, 7] . Furthermore, to the best of our knowledge, no studies have evaluated MST in 62 relation to different types of multiple therapeutic treatment within the same ACVIM C class 63 severity class.
64
The aim of DMVD treatment is to modulate hemodynamic and neurohormonal disorders, 65 including high venous pressures, reduce the systolic function, activate the sympathetic and 66 renin-angiotensin-aldosterone systems, and also release cytokines and vasopressin [1, 2] . Committee because this is a retrospective study carried out on data collected in subjects 94 routinely brought to a clinical examination by the owners.
95
From the beginning of the study to 2009, the admitted dogs were classified according to 96 ISACHC classes [16] , and from 2010 to 2018 according to the ACVIM classification [9] . In 97 order to compare the subjects, a univocal classification was needed, and the patients classified respiratory rate, cough, dyspnoea, ascites) [17] . In all subjects the presence and severity of PH 112 were evaluated, based on the TRV. The PH was classified as reported in the literature [18, 19] .
113
The accepted administered drugs were a combination of diuretics (furosemide), ACE-I
114
(benazepril, enalapril and ramipril), inodilator (pimobendan), and spironolattone. The 
Exclusion criteria
121
Clinical records of subjects affected by any other heart disease apart from DMVD and/or with 122 concurrent congenital heart disease and acquired cardiovascular disorders that could affect the 123 mitral valve or its functions (bacterial endocarditis, myocardial disease, arrhythmias) were 124 excluded. Subjects with primary hypertension were not included in the study [22] .
125
Incomplete clinical records or with missing information on the therapeutic protocol adopted 126 were also excluded.
127
Echocardiography
128
Echocardiographic examinations were performed on conscious dogs by specialists in up to the last time point at which they were known to be alive and were then removed from 144 the analysis.
145
The survival analysis was performed considering different end points such as death due to 146 other causes (OC), death related to the studied heart pathology (CD -cardiac death), first and 147 following therapy changes and moving to more advanced gravity class. The survival time in 148 the CD group was also analysed in relation to the therapeutic scheme.
149
The selected clinical records had to report the date and the medications prescribed as well as 150 any variation in therapy during the follow-up. were mixed breed, 20.5 (7.9%) Poodle, 20 (7.7%) Yorkshire Terrier, 13 (5.1%) Dachshund, 7
196
(2.8%) Shi-Tzu, 6 (2.6%) Pinscher, as well as lower percentages of other breeds .
197
The therapeutic groups considered in the first analysis are reported in Table 1. Table 2 MST was 318 days (Table 3) .
204
Univariate regression analysis showed the following variables to be statistically significant: 
209
Multivariate analysis highlighted that the LA/Ao ratio correlated negatively to MST and 210 significantly increased the risk of death (by 2.5 times) (Table 3) . 
211
Analysis of the groups of treatment in ACVIM class C (2001-2018)
235
The therapy groups in the ACVIM class C were 1, 2 and 3 (Table 1) . alive at the end of the study.
241
The MST of subjects that died of CD was 665 days in group 1, 487 days in group 2, and 447 242 days in group 3.
243
The univariate analysis revealed a positive correlation among the LA/Ao ratio, administration
of therapy (yes or no), E wave, E/A ratio, EDVI, ESVI, Allo(d) and Allo(s)), and CD. The
245
univariate analysis of the aforementioned variables was statistically significant for MST,
246
whose increase, increased the risk of death (Table 3) .
247
The multivariate analysis for subjects in class ACVIM C showed that only LA/Ao led to a 248 statistically significant difference in MST, and significantly increased (2.5 times) the risk of 249 CD, as described in Table 3 .
250
MSTs were also evaluated together with the influence of individual parameters on the MST 251 using univariate analysis and ANOVA tests between subjects with different types of therapy. 
279
The relationship between PH and CD was then investigated in each therapeutic group.
280
A weak and positive correlation was found in group 1 between the severity of PH and CD
281
(Kendall association coefficient R=0.24, p=0.023), while in groups 2 and 3, the correlation 282 was not statistically significant (R=0.13 and R=0.24, respectively). The distribution of PH severity among the three groups of dogs who died of CD is reported in 284 for age, PH severity was a risk factor for CD.
293
The regression model applied to each group of therapy evidenced different significant 294 correlations. In group 1 the following correlated significantly to CD: E wave, E/A ratio, group, the variables correlating significantly to CD were LA/Ao ratio, E wave, E/A wave,
299
EDVI, ESVI, Allo(d) and Allo(s) and PH severity.
300
We found a significant model only in therapeutic group 3, containing predictor LA/Ao 301 (HR=5.867, p=0.014) adjusted for age.
302
An analysis of the three different endpoints (EP) was performed for each group: CD, first and 303 following therapy changes and moving to more advanced gravity class.
304
The final step of the survival analysis entailed comparing the clinical findings and the 305 echocardiographic variables at the first and at the last visit for each subject. There was no 306 statistically significant difference between the first and last visit (p>0.05), except for the 307 echocardiographic variable related to the TRV (sign test, p=0.008). The difference in the tricuspid regurgitation velocity between the first and last visits was the 309 only parameter to be statistically significant (p=0.008) in animals subjected to a therapeutic 310 change in ACVIM C. the same severity class in relation to the various therapeutic combinations.
321
The demographic data of the studied population were in line with the data reported in the the two populations can be explained by the different classification applied during the study.
328
In veterinary medicine, in order to improve the diagnostic and therapeutic approach to CHF, 329 two classification schemes have been proposed: the ISACH classification and the ACVIM 330 classification [9, 16, 34] . In this study, it was assumed that for the records included from 2010 331 to 2018, there was a more standardised classification, not affected by conversion errors.
332
While the majority of dogs died or were euthanized because of worsening heart failure, 
344
The clinical records were analysed, the MST was calculated, and the various pharmacological 345 treatments and the changes in class during the follow-up period as well as the prognostic 346 factors were evaluated.
347
In this study the MST of ACVIM C patients belonging to different therapeutic groups was in 348 accordance with those reported in the literature, although the more complex therapeutic 349 scheme (groups 2 and 3) was associated with a shorter survival time [5, 13, 35, 36, 37] . This is 350 despite the fact that patients with more advanced DMVD need more complex cardioactive 351 therapy.
352
Our study highlighted that with the same severity level of DMVD (subjects in ACVIM class 
358
In line with the literature, we found that LA/Ao and E wave velocity are predictors of CD TRV correlated positively to CD in ACVIM C dogs undergoing therapeutic changes.
391
As far as the limitations of our study are concerned, this study was performed retrospectively 
395
The inclusion criteria of the patients were very strict. However, this is a retrospective study,
396
thus biases cannot be as well controlled as in a well-designed prospective study. Patients who 397 had already been treated with cardioactive therapy were recruited which justifies the 398 variability in therapeutic groups of the overall population.
399
The echocardiographic values, associated with ACVIM class of DMVD, were useful from a 400 prognostic point of view, and to answer any of the owners' questions.
401
The PH severity also correlated strongly to CD and therapeutic groups. In addition, we 402 believe that our study indicates that data regarding therapeutic choices and any variations after 
